Alzheimer's Disease Cooperative Study

ADCS的总体目标是推进可能有助于治疗、延缓或预防AD的干预措施的研究，特别是那些可能无法由工业界开发的干预措施。特别是，ADCS“专注于仪器和试验方法，以及潜在治疗方法的测试，否则制药行业可能不会研究这些治疗方法。在即将到来的拨款周期中，ADCS将继续努力通过对照临床试验、开发新仪器和试验设计、招募工作（特别注意招募少数民族受试者）来推进治疗。该组织将继续其最近对协作和数据共享的重视。具体目的：目的1：测试干预措施以改善认知，减缓衰退速度，或延迟/预防AD的发病。该申请中的四个项目中有三个旨在减缓疾病进展。目的2：测试改善行为症状的干预措施。我们将扩展有希望的早期结果，支持肾上腺素能方法改善行为症状，通过多中心试验吡唑嗪。目标3：设计用于临床试验的新仪器。对于目前的周期，我们已经将仪器开发纳入了我们最大的项目，即A4试验。目标4：为阿尔茨海默病临床试验设计开发新颖和创新的方法。A4试验采用了一种新的试验设计，在疾病的最早可行阶段，即临床前AD，测试一种领先的干预措施。目标5：开发新的和创新的阿尔茨海默病临床试验分析方法。生物统计学核心将继续努力推进AD试验设计的分析方法。将继续研究纵向数据的最佳建模，包括链接不同数据集的新方法。6:为目标。扩大阿尔茨海默病研究的个体范围，包括高危个体和轻度认知障碍患者。ADCS将其方法学研究重点放在早期试验上，在这个周期中，两个最大的项目针对临床前AD和轻度认知障碍。目标7：将少数群体纳入AD研究。在接下来的周期中，ADCS少数族裔招聘核心将扩大外联工作，我们将要求网站在我们的两个最大的试验中达到少数族裔招生目标。

The overall aim of the ADCS is to advance research in the development of interventions that might be useful for treating, delaying, or preventing AD, particularly interventions that might not be developed by industry. In particular, the ADCS "has focused on instrument and trial methodology, and the testing of potential therapeutics that might not otherwise be studied by the pharmaceutical industry. For the coming grant cycle, the ADCS will continue its efforts to advance therapeutics through controlled clinical trials, development o novel instruments and trial designs, recruitment efforts (with particular attention to recruitment f minority subjects). The organization will continue its recent emphasis on collaboration and data sharing. Specific Aims: Aim 1: Test interventions to Improve cognition, slow the rate of decline, or delay/prevent the onset of AD. Three of the four projects in this application aim to slow disease progression. Aim 2: Test an intervention to ameliorate behavioral symptoms. We will extend promising early results supporting an adrenergic approach amelioration of behavioral symptoms with a multicenter trial of prazosin. Aim 3: Design new instruments for use in clinical trials. For the present cycle, we have incorporated instrument development into our largest project, the A4 trial. Aim 4: Develop novel and innovative approaches to AD clinical trial design. The A4 trial utilizes a new trial design to test a leading intervention at the earliest feasible stge of disease, preclinical AD. Aim 5: Develop novel and innovative approaches to AD clinical trial analysis. The Biostatistics Core will continue efforts to advance analytical approaches to AD trial design. Work will continue on optimal modeling of longitudinal data, including novel methods to link diverse datasets. Aim 6:.Expand the range of individuals studied in AD studies to include at-risk individuals and those with MCI. The ADCS has focused its methodological research on early-stage trials, and for this cycle, the two largest projects target preclinical AD and mild cognitive impairment. Aim 7: Enhance the recruitment of minority groups into AD studies. For the coming cycle, the ADCS Minority Recruitment Core will expand outreach efforts, and we will require sites to meet minority enrollment targets in our two largest trials.